Unichem Laboratories Reports Q2 Revenue at Rs 640.22 Crore

Revenue rose to Rs 640.22 crore, while Net Profit stood at Rs 22.22 crore after a Rs 24.26 crore legal provision.

Reader Takeaway: Steady top-line growth is supported by core operations, though legal contingencies continue to weigh on quarterly bottom-line volatility.

What just happened

Unichem Laboratories released its consolidated financial results for the quarter ended September 30, 2026. The company posted revenue from operations of Rs 640.22 crore, up from Rs 632.62 crore in the previous quarter and Rs 578.96 crore in the same period last year. Profit before exceptional items and tax was reported at Rs 51.63 crore. However, a one-time exceptional charge of Rs 24.26 crore significantly impacted the final net profit, which settled at Rs 22.22 crore.

Why this matters

The exceptional charge is a provision for a legal claim filed by Laboratories Servier against Unichem and its subsidiary, Niche Generics Limited. The claim concerns damages sought by UK Health Authorities regarding Perindopril proceedings. The company has stated it intends to resolve this matter quickly, potentially through a compromise, to minimize further uncertainty.

Risks to watch

Investors should track the legal developments concerning Niche Generics Limited. The recurring nature of such regulatory and competition-related provisions in international markets creates unpredictability in earnings. Any further adverse rulings in the UK proceedings could pose a risk to future profit margins.

Context metrics

The company has maintained an 'Unmodified Audit Conclusion' for the quarter. While revenue has shown consistent year-on-year growth, the bottom line remains sensitive to international legal liabilities that management must navigate.